Clinical Trials
- A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
- An Observational Study on Epithelioid Sarcoma
- Epithelioid Sarcoma Natural History Study
- Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
- Tazemetostat Expanded Access Program for Adults With Solid Tumors
- Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations
- Painful Channelopathies Study
- Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
- Spinal Cord Stimulation for Refractory Pain in Erythromelalgia
- Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)
- Vascular and Neurologic Exploration of Small Nervous Fiber by Sudoscanner and QST
- Application of Enhanced Recovery After Surgery for Congenital Esophageal Atresia During Perioperative Period
- Cardiorespiratory Performance and Pulmonary Microbiome in Patients After Repair of Esophageal Atresia
- Dumping Syndrome After Operation of Esophageal Atresia Type III
- Dumping Syndrome and Esophageal Atresia
- Endoscopic Ultrasound Findings in Esophageal Atresia Following Surgical Repair
- Esophageal Atresia: a Natural Experiment of the Effects of Oral Inoculation on the Gut Microbiome
- Evaluation of the Respiratory Impact After Conventional or Minimally Invasive Esophageal Atresia Surgery
- Flourish™ Pediatric Esophageal Atresia
- Fluid Overload and Pulmonary Function
- Individualized Management for Long Gap Esophageal Atresia
- Management of Esophagitis Following Repair of Esophageal Atresia
- Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health
- Oral Viscous Budesonide in Anastomotic Stricture After Esophageal Atresia Repair (OVB in EA)
- Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
- Respiratory Complications of Operated Esophageal Atresia in Children
- Study in Children With the Diagnosis of Congenital Diaphragmatic Hernia (CDH) and Oesophageal Atresia (EA)
- The Effect of Dexmedetomidine on Oxygen During One Lung Ventilation in Pediatric Surgery.
- “Evaluation of the PillCam™ESO Capsule in the Detection of Esophageal Varices
- A Study of Disposable Transnasal Esophagoscope
- Banding Versus Propranolol for Primary Prophylaxis of Variceal Bleeding
- Blood Ammonia as Predictor for Esophageal Varices and Risk of Bleeding
- Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding
- Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled Study
- Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices
- Enhancing Detection of Small Esophageal Varices by PillCam ESO
- EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal Bleeding
- Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices
- MCCE in Assessing Efficacy of Gastro-oesophageal Varices
- Noninvasive Methods For Prediction of Esophageal Varices in Children
- Optimal Time for Follow up After Variceal Band Ligation
- PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES?
- Self-expandable Esophageal Stent Versus Balloon Tamponade in Refractory Esophageal Variceal Bleeding.
- Study of Capsule Endoscopy to Determine the Accuracy for Detection of Esophageal Varices
- The Accuracy and Acceptability of Magnet Assisted Capsule Endoscopy in the Diagnosis of Esophageal Pathology: a Pilot Study
- Transparent Cap-assisted Endoscopic Sclerotherapy
- Two-dimensional Shear-Wave Elastography Evaluate Esophageal Varices Bleeding Risk of Liver Cirrhosis
- A Bioequivalence Study of L04TD1 Compared to Administration of L04RD1 in Healthy Volunteers
- A Bioequivalence Study of L04TD2 Compared to Administration of L04RD1 in Healthy Volunteers
- A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy
- A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers
- A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers
- A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
- A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension
- A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
- A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699, a New Experimental Antihypertensive Drug, in Patients With Essential Hypertension
- A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
- A Phase 3 Study to Evaluate and Compare the Efficacy and Safety of 8-week Treatment With AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
- A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
- A Study for Post-Marketing Surveillance of Azilsartan Medoxomil in the Treatment of Adult Participants With Essential Hypertension in South Korea
- A Study for Post-marketing Surveillance of Azilsartan Medoxomil/Chlorthalidone Fixed Dose Combination (FDC) in the Treatment of Participants With Essential Hypertension in South Korea
- A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects
- A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers
- A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers
- A Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers
- A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone
- A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy
- A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
- A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia
- A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers
- A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers
- A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension
- A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension
- Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
- Amlodipine as add-on to Olmesartan in Hypertension
- Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial
- An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
- Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations
- Autonomic Imbalance and 24-h Blood Pressure Change in Patients With Chronic Renal Disease
- Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
- Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
- Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions
- Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions
- BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination
- Canrenone as Add-on in Patients With Essential Hypertension
- Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients
- Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
- Clinical Trial on Remote Ischemic Conditioning and Hypertension（HOPE）
- Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension
- Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
- Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets
- Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia
- Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
- Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension
- Comparison of Awakening Versus Bedtime Dosing of Aspirin in Pre-Hypertension or Mild Essential Hypertension
- Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
- Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
- Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
- Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function
- Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
- Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy
- Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
- Effect of Acupuncture on Patients With Mild Hypertension
- Effect of Atorvastatin on Carotid Intima Media Thickness
- Effect of Breathing and Muscle Relaxation Technique in Individual With Essential Hypertension
- Effect of Motivational Interviews on Cardiovascular Disease Risks and Healthy Lifestyle Behavior Changes
- Effect of Renal Denervation on NO-mediated Sodium Excretion and Plasma Levels of Vasoactive Hormones
- Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension
- Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients
- Effects of Aromatherapy in Hypertensive Individuals
- Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension
- Effects Of Losartan On Myocardial Structure In Diabetic Hypertensive Patients With Left Ventricular
- Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure
- Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
- Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
- Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
- Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
- Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
- Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension
- Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
- Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
- Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control
- Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia
- Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
- Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
- Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
- Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension
- Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension
- Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension
- Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension
- Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
- Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
- Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
- Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
- Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients
- Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
- Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension
- Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
- Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Fields in Mild and Moderate Essential Hypertension
- Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy
- Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
- Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension
- Efficacy of Rostafuroxin in the Treatment of Essential Hypertension
- Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
- Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension
- Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)
- Essential Hypertension
- Evaluation of a Transmedial Psychoeducational Program to Improve Pharmacological Adherence
- Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine
- Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes
- Evaluation of Stendo Pulsating Suit on Microcirculation and Central Blood Pressure in Essential Hypertension Patients
- Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension
- Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.
- Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects
- Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects
- Fimasartan Achieving SBP Target (FAST) Study
- FimasaRtan-basEd BP Targets After Drug SwitcHing
- Fimasartan/Amlodipine Combination Phase III
- GRK4 Polymorphisms Blood Pressure Response to Candesartan
- Heart Rate Variability in White Coat Hypertension and Essential Hypertension
- Heat Therapy in Older Hypertensive Women
- Helius in Hypertension-I: The UK Hypertension Registry
- Home Blood Pressure in Hypertension Management
- Hybrid Blood Pressure Monitor Validation
- Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)
- Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension
- Hypertension: Prediction of Biofeedback Success
- Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension
- In-practice Evaluation of Atacand 16mg Antihypertensive Effect
- Inflammatory Response to Salt in Essential Hypertension
- Intensive Vasodilator Therapy in Patients With Essential Hypertension
- Juvenile Essential Arterial Hypertension and Vascular Function
- L-Arginine Metabolism in Essential Hypertension
- Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea
- LCZ696 in Advanced LV Hypertrophy and HFpEF
- Loaded Breathing Training in Essential Hypertension
- Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
- Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension
- Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension
- Motivational Interviewing
- Non-pharmacological Treatment for Essential Isolated Systolic Hypertension in Elderly
- Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension
- Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure
- Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
- Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
- Olmesartan as an add-on to Amlodipine in Hypertension
- Olmesartan in Essential Hypertension
- Olmesartan Medoxomil in Atherosclerosis
- Olmesartan Medoxomil in Hypertension and Renal Impairment
- Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly
- Olmesartan Medoxomil Versus Losartan in Patients With Hypertension
- Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
- Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension
- Perindopril Amlodipine for the Treatment of Hypertension
- Personal Activity Intelligence in the Treatment of High Blood Pressure
- Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension
- Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study
- Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension
- Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension
- Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo
- Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
- Physical Activity, Air Pollution, and High Blood Pressure
- PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension
- Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)
- Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
- Protective Effect of Beraprost Sodium Tablets on Reperfusion Therapy for Acute STEMI
- RAS Peptide Profiles in Patients With Arterial Hypertension
- Renal Sympathetic Modification in Patients With Essential Hypertension
- Resistant Arterial Hypertension Cohort Study
- S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension
- s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension
- Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension
- Safety and Efficacy of Remote Ischemic Conditioning in Patients With Essential Hypertension (SERIC-EH)
- Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension
- Safety Study of RMJH-111b to Treat Essential Hypertension
- Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension
- Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension
- Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension
- Study MIPAE – Melatonin and Essential Arterial Hypertension
- Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension
- Study of CS-3150 in Patients With Essential Hypertension
- Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
- Study of Personalized Dietary Intervention for the Control of Essential Hypertension
- Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects
- Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasartan (BR-A-657∙K) in Healthy Elderly and Young Male Volunteers
- Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg
- Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
- Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine
- Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.
- The Confirmatory Olmesartan Plaque Regression Study
- The Effect of a Homoeopathic Complex on Blood Pressure in Refractory Hypertension
- The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension
- The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension
- The Effect of the Use of BATHE Interview Technique on Treatment Compliance in Hypertension Patients in Primary Care
- The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables
- The Effects of Nebivolol on the NO-system in Patients With Essential Hypertension
- The Effects of Social Support and Oxytocin Administration on Physiological Stress Reactivity in Essential Hypertension
- The Northwest Coalition for Primary Care Practice Support
- The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.
- To Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers
- Treatment of HYpertension: Morning Versus Evening
- Uric Acid in Essential Hypertension in Children
- Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
- Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients
- Vascular Impact of Omega-3 in Metabolic Syndrome
- Vedic Medical Astrology in Essential Hypertension
- 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia
- A Study Designed to Assess the Efficacy, Safety, and Tolerability of P1101 After the 12 Month Core Treatment Period in Patients With ET.
- Anagre Cap. in Patients With High-Risk Essential Thrombocythemia
- Anagrelide Retard in Essential Thrombocythemia
- Anagrelide Retard vs. Placebo: Efficacy and Safety in “At-risk” Patients With Essential Thrombocythaemia
- Anagrelide vs. Hydroxyurea – Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia
- CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms
- French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
- Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
- IMG-7289 in Patients With Essential Thrombocythemia
- Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
- Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood Essential Thrombocythemia
- Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
- Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
- The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)
- The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
- [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson’s Diseases and Essential Tremor
- 1-Octanol to Treat Essential Tremor
- 1-Octanol to Treat Essential Tremor
- A Clinical Study to Evaluate CAD-1883 in Essential Tremor
- A Clinical Trial of 3 Doses of PRAX-944 in Participants With Essential Tremor
- A Clinical Trial of PRAX-114 in Participants With Essential Tremor
- A Clinical Trial of PRAX-944 in Participants With Essential Tremor
- A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.
- A Pilot Clinical Trial Of Memantine for Essential Tremor
- A Pilot Efficacy and Safety Study of ST101 in Essential Tremor
- A Pilot Study of the Cala ONE Device for Essential Tremor
- A Pilot Study to Assess the Effects of Pre-SMA LF-rTMS for the Treatment of Essential Tremor
- A Safety/Efficacy Trial of Zonisamide for Essential Tremor
- A Second Magnetic Resonance Guided Focused Ultrasound Thalamotomy for Essential Tremor
- A Study of T2000 in Essential Tremor
- A Study to Evaluate SAGE-217 in Subjects With Essential Tremor
- A Study to Evaluate the Effectiveness and Safety of ExAblate MRgFUS on Essential Tremor
- A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
- A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
- A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm
- Abbott DBS Registry of Outcomes for Indications Over Time
- Adaptive Portable Essential Tremor Monitor
- Algorithms for Programming DBS Systems for ET
- Alternating Current Stimulation for Essential Tremor
- An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor
- Analysis and Suppression of Tremor During Grasp Using Ultrasound Imaging and Electrical Stimulation
- Ataxia in Essential Tremor: Describing the Differences Between Disease Process and Treatment Effect
- Atlas Predicted DBS Settings in Essential Tremor
- Battery-preserving Stimulation Patterns for Deep Brain Stimulation
- Bilateral Essential Tremor Treatment With FUS
- Bilateral Essential Tremor Treatment With Gamma Knife
- Bilateral Treatment of Medication Refractory Essential Tremor
- Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
- Brain Networks and Consciousness
- Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
- Cala ONE Device for Essential Tremor
- Cerebellar rTMS for Essential Tremor
- Cerebello-thalamo-cortical Coupling in Essential Tremor
- Characterization of Complex Pulse Shapes in Deep Brain Stimulation for Movement Disorders Using EEG and Local Field Potential Recordings
- Chinese ET Registry (CETR)
- Chronic Versus Intermittent Deep Brain Stimulation for Essential Tremor
- Clinical and Physiological Studies of Tremor Syndromes
- Clinical Outcomes for Deep Brain Stimulation
- Clinical Profile in Patients With Essential Tremors
- Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor
- Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson’s Disease (PD) or Essential Tremor (ET)
- Comparison of Botulinum Toxin Injections in Forearm FLexor Plus EXtensor Muscles vs. Flexor Muscles Alone for Treatment of Essential Hand Tremor(FLEX-D ET)
- Comparison of the Electric Plasma Surgical Tool “PlasmaBlade” for Replacement of the Deep Brain Stimulation (DBS) Devices With Conventional Surgery
- Continued Access Protocol: ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors
- Continuous Tremor Assessment During Daily Activities
- Cortical-Basal Ganglia Speech Networks
- Cyclic Deep Brain Stimulation in Essential Tremor
- DBS of Posterior Subthalamic Area (PSA) and Ventral Intermediate Nucleus (VIM) in Essential Tremor (ET)
- Decision-making and Emotion Recognition in Essential Tremor
- Deep Brain Stimulation (DBS) Data Base Study
- Deep Brain Stimulation (DBS) for the Suppression of Tremor
- Deep Brain Stimulation (DBS) Retrospective Outcomes Study
- Deep Brain Stimulation Effects in Essential Tremor
- Deep braIn Stimulation for Tremor TractographIC Versus Traditional
- Deep Brain Stimulation for Voice Tremor: Left, Right, or Both Hemispheres?
- Deep Brain Stimulation Surgery for Movement Disorders
- Demand-driven Management of Essential Tremor
- Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation
- Directional Versus Nondirectional DBS for ET
- Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor
- Dual Lead Thalamic Deep Brain Recording (DBR)-DBS Interface for Closed Loop Control of Severe Essential Tremor
- Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001)
- Effects of Octanoic Acid for Treatment of Essential Voice Tremor
- Effects of Stimulation Patterns of Deep Brain Stimulation
- Efficacy of Levetiracetam in Essential Tremor
- Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor
- Electroclinical Correlates in Essential Tremor
- Elucidating the Temporality of Structural and Functional Connectivity Changes in Essential Tremor After Successful Deep Brain Stimulation to the Dentato-rubro-thalamic Tract
- Environmental Epidemiology of Essential Tremor
- Essential Tremor in Children and Adolescent
- Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation
- Ethanol Response in Essential Tremor: Clinical and Neurophysiological Correlates
- Evaluate SAGE-547 in Patients With Essential Tremor
- Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor
- Evaluation of Directional Recording and Stimulation Using spiderSTN
- Evaluation of Directional Stimulation During the Implantation of Deep Brain Stimulation (DBS) Leads
- Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool
- ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) for Treatment of Tremor
- ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors
- ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor
- ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor
- Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation
- Experimental Therapeutics in Essential Tremor Using Transcranial Direct Current Stimulation
- Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response
- Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy
- Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Essential Tremor
- GADGET-PD Genetic and Digital Diagnosis of Essential Tremor and Parkinson’s Disease Trial
- Gamma Knife Radiosurgery for Treatment of Essential Tremor
- Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:
- Imaging in the Diagnosis of Parkinson’s Disease and Essential Tremor
- Impact of a Standardized Music Therapy Protocol on the Quality of Life of Patients With Abnormal Movements Treated With Continuous Electrical Neuromodulation
- Interphase Gap in Biphasic Stimulation in DBS for ET
- Investigating the Use of Complex Pulse Shapes for DBS in Movement Disorders
- Kinematic-based BoNT-A Injections for Bilateral ET
- Limb Cooling in Essential Tremor
- Linac FRACtionated Radiosurgical THALamotomie in Tremors (FRACTHAL)
- Local Fields Potentials Recorded From Deep Brain Stimulating Electrodes
- Long-Term Transcutaneous Stimulation and Essential Tremor: A PET Study
- Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement Disorders
- Mapping Functional Networks of Brain Activity Using EEG in Patients With Essential Tremor or Parkinson Disease Before and After MR-guided Focused Ultrasound Thalamotomy for Tremor
- Modulatory Effects of Deep Brain Stimulation on Cerebral Cortical Activity
- Motor Network Physiology
- Motor-related Cortical Potential in Patients With Essential Tremor
- Movement Disorder Quantification Algorithm Development
- MRI Study of Infinity DBS System
- Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor
- National Survey of Essential Tremor Plus in China
- Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
- Neurophysiologic Assessment of ET Patients Treated by Vim DBS
- Neurophysiologic Study of Patient With Essential Tremor and Dystonic Tremor
- Neurotransmitter Measurements Using (WINCS) During Deep Brain Stimulation Neurosurgery
- Next-Generation Pre-Operative Targeting for Thalamic DBS in the Treatment of Tremor
- Novel Therapies for Essential Tremor
- Octanoic Acid for Essential Tremor
- Octanol to Treat Essential Tremor
- Open Label Study for the Use of Transcranial Ultrasound Treatment of Tremor
- Optimization of VIM Targeting in Essential Tremor Surgery
- Optimizing DBS Electrode Placement and Programming
- Pathophysiology of Tremor-modulating Mechanisms of Propranolol and Primidone in Essential Tremor
- Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
- Physiological Brain Atlas Development
- Physiology, Imaging and Modeling of Essential Tremor
- Pre-lemniscal Radiation Deep Brain Stimulation for ET
- Pregabalin (Lyrica) for the Treatment of Essential Tremor
- Pregabalin in the Treatment of Essential Tremor
- Probabilistic Targeting of the VIM
- Propranolol and Botulinum Toxin for Essential Vocal Tremor
- Prospective Study for Symptomatic Relief of ET With Cala Therapy
- RAD 1601: EDGE Radiosurgery for Intractable Essential Tremor and Tremor-Dominant Parkinson’s Disease
- RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)
- Relief From Side Effects: Clinical Use of Electrodes With Direction
- Repetitive Transcranial Magnetic Stimulation in Essential Tremors Patients
- Responsive Deep Brain Stimulator for Essential Tremor
- RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor
- Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor
- Sensory Gating Measured With Microelectrode Recording (MER) During Deep Brain Stimulation (DBS) Surgery
- Sensory-specific Peripheral Stimulation for Tremor Management
- Staged Bilateral Exablate Treatment of Medication Refractory Essential Tremor
- Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- Study to Evaluate SAGE-324 in Participants With Essential Tremors
- Symptomatic Relief of Action Tremor With Cala Trio Using Trio+ Bands
- T2000 in Essential Tremor – Open Label Continuation
- Thalamic LFPs and VIM DBS in Essential Tremor: Correlation, Evolution, and Therapeutic Perspectives
- The Effectiveness of Alternating Stimulation in Preventing Tolerance in Essential Tremor Patients
- The Effects of Vibrotactile Stimulation in Patients With Movement Disorders
- The Essential Tremor (ET) and Parkinson Disease (PD) Tremor Acute Stimulation Study
- The Motor Network in Essential Tremor: Mechanisms of Therapy
- The Relationship of Muscle Strength With Functional Skills in Geriatric Individuals With Essential Tremor
- The Swedish Essential Tremor (SWEET) Trial
- Transcranial Direct Current Stimulation of the Motor Cortex in Essential Tremor
- Transcranial Stimulation for Essential Tremor
- Transcranial Ultrasound Therapy of Essential Tremor
- Tremor Monitoring Device
- Trial of Cannabis for Essential Tremor
- tSMS in Essential Tremor
- Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders
- Ventrointermediate Nucleus (VIM DBS) and Working Memory
- VIM DBS Respiratory Modulation: N-of-1 Trial
- Wearable Sensor for Responsive DBS for ET
- WiiMote Game Controller as a Device to Study Movement Disorders
- Zonisamide in the Treatment of Essential Tremor
- A Study Investigating Treatment Factor X in People With Factor X Deficiency
- A Study to Investigate Bio Product Laboratory Ltd (BPL’s) Factor X in the Prophylaxis of Bleeding in Children
- Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery
- Safety & Efficacy of BPL’s High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery
- A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
- A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
- An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
- Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
- Factor XIII and Pulmonary Embolism in Neurosurgical Patients
- Wound Healing Abnormalities in Major Abdominal Surgery
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
- A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
- A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
- A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
- A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
- A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
- A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers
- A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- A Phase II Study Evaluating the Effect of GEN-1 on SLL When Administered in Combination With Bevacizumab and NACT in Subjects Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
- A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
- A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
- A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
- A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers
- A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
- A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
- A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
- A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
- A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
- A Study LY2228820 for Recurrent Ovarian Cancer
- A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
- A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
- A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
- A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
- A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
- A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
- A Study of Long-Term Responders on Olaparib
- A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
- A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
- A Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
- A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
- A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer
- A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
- A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
- A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
- A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
- A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
- A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
- A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
- A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208)
- A Study of XMT-1660 in Participants With Solid Tumors
- A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
- A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer
- A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
- A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
- A Trial Evaluating TG4050 in Ovarian Carcinoma.
- A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
- A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
- A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer
- A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
- Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
- Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer
- Accelerating Gastrointestinal Recovery
- Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
- Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer
- Adaptive Therapy (AT) With Carboplatin in Patients With Relapsed Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
- Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
- Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
- AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
- AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
- Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain – A GEICO Study
- Anti—PD-L1 and SAbR for Ovarian Cancer
- ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
- Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
- Autologous OC-L Vaccine and Ovarian Cancer
- Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
- Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma
- Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
- Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
- AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
- BEACON – ABC in Recurrent Platinum Resistant HGSOC
- Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
- Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
- Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma
- Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
- BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
- Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum
- Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage
- Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182
- Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer
- Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
- BrUOG 390: Neoadjuvant Treatment With Talazoparib
- Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
- Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse
- Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
- Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
- Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Carboplatin, Gemcitabine Hydrochloride, and ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer
- Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
- Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
- Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
- Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
- Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
- Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
- Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer
- Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
- Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane
- Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
- Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
- Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
- Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
- Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
- Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
- Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer
- Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
- Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
- Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
- Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery
- Computed Tomography Perfusion Imaging in Predicting Outcomes in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Receiving Bevacizumab
- Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
- Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
- Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
- CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
- CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer
- Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma
- Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
- DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
- Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
- Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients
- Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
- Depression Treatment and Screening in Ovarian Cancer Patients
- Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer
- Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
- Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
- Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
- Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
- Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
- Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
- Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
- Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer
- Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
- Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer
- Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
- Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer
- Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery
- EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT
- Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
- Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
- Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
- Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
- Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
- Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
- Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study
- Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives
- Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients
- Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy
- Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
- Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
- First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer
- Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission
- GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
- Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
- Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
- Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Genomic BRCA and Extensive ovArian Cancer Testing
- Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer
- Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
- Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer
- Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
- High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy
- HIPEC After Initial CRS in Patients Who Have Received NACT
- HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma
- Homologous Recombination Inquiry Through Ovarian Malignancy Investigations
- HOT: HIPEC in Ovarian Cancer as Initial Treatment
- Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer
- Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer – A Feasibility Study
- IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
- ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
- IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer
- Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
- Interactive Educational Website for Women With Ovarian Cancer & Caregivers
- Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
- Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
- Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients
- Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin
- Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
- Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
- Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
- Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer
- Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
- Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
- Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
- Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
- Japan Phase 2 Study of Niraparib in Patients With Advanced, Relapsed Ovarian Cancer
- Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer
- KORE-Innovation: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients With Ovarian Cancer
- Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers
- LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer
- Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
- Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Letrozole in Patients With Ovarian Tumors
- Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
- Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
- Low Dose Cyclophosphamide +/– Nintedanib in Advanced Ovarian Cancer
- Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
- Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer
- Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
- Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival
- Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
- Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
- Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
- Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
- Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
- MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
- Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR
- Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
- Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive
- Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
- Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel Bevacizumab for Primary Ovarian
- Neoadjuvant Therapy for Ovarian Cancer
- Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer)
- Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
- Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
- Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
- Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
- NiraParib Maintenance After Carboplatin and Paclitaxel in optimaLly debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
- Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
- Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
- Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
- Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
- Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
- ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
- ONC201 and Paclitaxel in Treating Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Open-Label Study to Evaluate Mirvetuximab Soravtansine in Cancers With High Folate Receptor-Alpha Expression
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
- OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
- Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia
- Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma
- p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
- p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
- Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
- Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer
- Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
- Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
- PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
- Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
- Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
- PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.
- PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
- Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
- Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
- Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
- Pemetrexed Disodium and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- PET Imaging of Ovarian Carcinoma With 18F-FSPG
- PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer
- Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
- Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
- PH3 Study of Mirvetuximab Soravtansine vs Investigator’s Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
- Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
- Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer
- Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
- Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
- Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
- Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer
- Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
- Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
- Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
- Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab
- Phase 3 Study of Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
- Phase II ABT-888 With Cyclophosphamide
- Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma
- Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer
- Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer
- Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Pilot Study of Durvalumab and Vigil in Advanced Women’s Cancers
- Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
- Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
- Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)
- Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
- Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Prospective Cohort Study of Variant Carriers With BRCA1 or BRCA2
- Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients
- Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass
- PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer
- Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
- Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
- Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer
- Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
- Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
- Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
- Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention – US Cohort Study
- RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer
- Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
- S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer
- S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
- S9912 Combination Chemo in Stage III Ovarian Cancer,
- Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
- Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
- Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
- SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)
- Search for Predictors of Therapeutic Response in Ovarian Carcinoma
- Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
- Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies
- Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
- Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
- Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube
- SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care
- Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin
- Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
- Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
- Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
- Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer
- Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer
- Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer
- Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
- Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
- Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer
- Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
- Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43)
- Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
- Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
- Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2)
- Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
- Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
- Study of Paclitaxel in Patients With Ovarian Cancer
- Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
- Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Ovarian Cancer
- Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer
- Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
- Study of Ramucirumab in Ovarian Cancer
- Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer
- Study of REGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer.
- Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
- Study of Safety & Biological Activity of IP GEN-1 With Neoadjuvant Chemo in Ovarian Cancer
- Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
- Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
- Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
- Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients
- Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer
- Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
- Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
- Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
- Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
- Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
- Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
- Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
- Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
- Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
- Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Testing the Addition of an Anti-Cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Solid Tumors, Pancreatic Cancer, and Ovarian Cancer
- Testing the Combination of APG-1252 and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
- Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
- The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer
- The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer
- The Treatment Preferences of Women Diagnosed With Ovarian Cancer
- Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
- Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Tivozanib As Maintenance Therapy In GYN
- Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
- Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
- Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
- Total/Subtotal Colectomy in Ovarian Cancer
- Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy
- Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction
- Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
- Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
- Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma
- Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
- TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
- TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
- Tumor Treating Fields Therapy in Combination With Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
- UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
- UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Using Aspirin to Improve Immunological Features of Ovarian Tumors
- Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
- Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
- Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
- Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
- Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
- Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
- VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
- Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
- Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
- Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
- Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer
- Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
- Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy
- Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer
- Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
- VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer
- Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
- ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer